The effects of androgen deprivation therapy on the 18f-choline uptake in prostate cancer patients undergoing neoadjuvant treatment

Article Figures & Data

Table 1. Differences between groups

Variables	Group 1 (NO)	Group 2 (YES)	P value
N patients	62	17
Median age	71 (41-87)	69 (62-82)	0.887
Gleason score categories 7 8-10	23 (37%) 39 (63%)	5 (29%) 12 (81%)	0.557
PSA levels (before PET)	18.15 (2.80-201.00)	25.00 (0.00-288.00)	0.234
PSA categories 20 ng/mL	13 (21%) 19 (31%) 24 (48%)	4 (24%) 2 (12%) 7 (64%)	0.423
NCCN category Intermediate High	14 (23%) 48 (77%)	3 (18%) 14 (82%)	0.661
PET positivity Prostate Prostate+LN Prostate+LN+bone Prostate+bone Prostate+others	40 (65%) 12 (19%) 4 (6%) - 6 (10%)	14 (82%) - - 3 (18%) -	<0.001
SUVmax in prostate	7.72 (3.01-29.61)	5.34 (2.96-17.91)	0.020
Treatments RP RP+adjuvant ther RT+ADT ADT Others	21 (34%) 1 (2%) 22 (35%) 16 (26%) 2 (3%)	4 (24%) 1 (6%) 8 (44%) 4 (24%) 0	0.652